Vertex Pharmaceuticals
VRTX
1,547 hedge funds and large institutions have $110B invested in Vertex Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 173 funds opening new positions, 660 increasing their positions, 515 reducing their positions, and 92 closing their positions.
88% more first-time investments, than exits
New positions opened: 173 | Existing positions closed: 92
28% more repeat investments, than reductions
Existing positions increased: 660 | Existing positions reduced: 515
12% more capital invested
Capital invested by funds: $97.7B → $110B (+$12.2B)
10% more funds holding in top 10
Funds holding in top 10: 30 → 33 (+3)
4% more funds holding
Funds holding: 1,494 → 1,547 (+53)
0.13% more ownership
Funds ownership: 91.02% → 91.15% (+0.13%)
22% less call options, than puts
Call options by funds: $681M | Put options by funds: $875M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$1.21B |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$495M |
| 3 |
DZ Bank
Frankfurt Am Main,
Germany
|
+$344M |
| 4 |
Swedbank
Stockholm,
Sweden
|
+$289M |
| 5 |
Goldman Sachs
New York
|
+$287M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$990M |
| 2 |
BlackRock
New York
|
-$281M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$201M |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
-$189M |
| 5 |
ClearBridge Investments
New York
|
-$147M |
VRTX Hedge Fund Activity: Q2 2024 in Review
1,547 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q2 2024, worth a combined $110B — up 12% from $97.7B a quarter earlier.
Buyers outnumbered sellers: 173 funds opened new VRTX positions and 92 closed out — a net gain of 81 holders — while 660 added to existing stakes and 515 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $1.21B. The largest seller was T. Rowe Price Associates, cutting an estimated $990M.
- 1,547 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q2 2024, up from 1,494 in Q1 2024.
- Funds reported $110B of Vertex Pharmaceuticals stock for Q2 2024, up 12% quarter-over-quarter.
- 173 funds opened new Vertex Pharmaceuticals positions in Q2 2024 and 92 closed out, a net change of +81 holders.
- The largest Vertex Pharmaceuticals buyer in Q2 2024 was Capital Research Global Investors, an estimated $1.21B added.
- The largest Vertex Pharmaceuticals seller in Q2 2024 was T. Rowe Price Associates, an estimated $990M sold.
Based on aggregated 13F filings for Q2 2024.